Abstract:Background/aim: Superoxide dismutase (SOD) is the critical enzyme in the detoxification of superoxide radicals because those are the first species produced in the majority of biological free radical producing reactions. Inconsistent data are present about SOD activity in patients with schizophrenia. Numerous studies have shown that SOD has been elevated in chronic schizophrenic patients. However, decreased SOD activity was found in neuroleptic naïve, first episode schizophrenic patients, in chronic-medicated patients and in chronic-unmedicated patients. The aim of this study was to examine which of the following factors including age, gender, the onset of the disease, the duration, the number of episodes, heredity, psychopathologic symptoms and drug treatment could affect erythrocyte SOD activity in patients with schizophrenia. Methods: This study included 68 consecutive patients with schizophrenia (29 males and 39 females) ranging in age from 18 to 61 years, divided into two age groups (<34 years and >34 years). SOD activity was measured in erythrocyte hemolyzates by Ransod commercially available test. Results: In the group of patients younger than 34 years SOD levels were significantly higher (1381±273 U/gHb, p=0.038) compared to the levels of the older group (1231±206 U/gHb). Gender and heredity did not induce any significant difference in SOD activity between younger and older subgroups. A significant difference in enzyme activity was found between the younger and older subgroups having the onset of the disease after 24 years of age (1408±217 U/gHb vs. 1252±213 U/gHb, p=0.031). The patients of the younger group who had more than one psychotic episode had significantly higher SOD activity (1492±298 U/gHb; p=0.009) than those who had only one episode (1256±177 U/gHb), as well as than the older subgroup with more than one episode (1253±231 U/gHb; p=0.014). Although the duration of the disease did not induce any significant difference in enzyme activity between younger and older subgroups, a significant negative correlation was obtained between SOD activity and the duration of the disease (r=-0.511, p<0.01). No significant differences were found in SOD activity between the subgroups with different PANSS scores. First generation antipsychotics were associated with elevated enzyme activity in both groups. Simultaneous treatment of patients with first generation antipsychotics and second generation antipsychotics induced a significant decrease in SOD activity in the younger group. Conclusion: Our results show that erythrocyte SOD activity is increased in the early phase of schizophrenia and that depends on age of onset of the disease, the number of psychotic episodes, the duration of the disease and medical treatment.

Elevated activity of superoxide dismutase in male late-life schizophrenia and its correlation with clinical symptoms and cognitive deficits

Imbalanced Free Radicals and Antioxidant Defense Systems in Schizophrenia: A Comparative Study

Plasma Superoxide Dismutase Activity in Relation to Disability in Activities of Daily Living and Objective Physical Functioning among Chinese Older Adults

Oxidative Stress Markers and Metal Ions Are Correlated with Cognitive Function in Alzheimer’s Disease

Low Serum Superoxide Dismutase is Associated with a High Risk of Cognitive Impairment after Mild Acute Ischemic Stroke

Clinical Symptoms and Cognitive Impairment Associated with Male Schizophrenia Relate to Plasma Manganese Superoxide Dismutase Activity: a Case-Control Study.

Elevated activity of plasma superoxide dismutase in never-treated first-episode schizophrenia patients: Associated with depressive symptoms

Age-related changes of superoxide dismutase activity in patients with schizophrenia

Differential Impacts of Endogenous Antioxidants on Clinical Symptoms and Cognitive Function in Acute and Chronic Schizophrenia Patients

Cognitive Impairment and Psychopathology Are Related to Plasma Oxidative Stress in Long Term Hospitalized Patients With Chronic Schizophrenia

Elevated Blood Superoxide Dismutase in Neuroleptic-Free Schizophrenia: Association with Positive Symptoms

Superoxide Dismutase and Cytokines in Chronic Patients with Schizophrenia: Association with Psychopathology and Response to Antipsychotics

Superoxide Dismutase Modified the Association of Serum Malondialdehyde Levels with Cognitive Decline Among Older Adults: Findings from the Chinese Longitudinal Healthy Longevity Survey

Sex-specific association between peripheral superoxide dismutase, BDNF and cognitive impairment in drug-naive first episode patients with schizophrenia

Cognition Impairment in Schizophrenia Patients with Tardive Dyskinesia: Association with Plasma Superoxide Dismutase Activity.

Serum Oxidative Stress Marker Levels in Unmedicated and Medicated Patients with Schizophrenia

Decreased Peripheral BDNF Levels and Cognitive Impairment in Late-Life Schizophrenia

Association between MnSOD Activity and Cognitive Impairment in Unmedicated First-Episode Schizophrenia: Regulated by MnSOD Ala-9Val Gene Polymorphism

The relationship between the gut microbiota and oxidative stress in the cognitive function of schizophrenia: A pilot study in China

Antioxidant Enzymes and Lipid Peroxidation in Different Forms of Schizophrenia Treated with Typical and Atypical Antipsychotics.

Blood Superoxide Dismutase Level in Schizophrenic Patients with Tardive Dyskinesia: Association with Dyskinetic Movements